Jim Simons Pacira Bio Sciences, Inc. Transaction History

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,992,601 shares of PCRX stock, worth $51.3 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

1,992,601

Previous 1,978,997 0.69%

Holding current value

$51.3 Million

Previous $29.8 Million 25.96%

% of portfolio

0.06%

Previous 0.05%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$15.3 - $20.33 $208,141 - $276,569	13,604 Added 0.69%	1,992,601 $37.5 Million
Q3 2024 Nov 13, 2024	SELL	$11.7 - $28.46 $1.02 Million - $2.48 Million	-87,200 Reduced 4.22%	1,978,997 $29.8 Million
Q2 2024 Aug 09, 2024	BUY	$25.5 - $31.51 $4.69 Million - $5.8 Million	184,000 Added 9.78%	2,066,197 $59.1 Million
Q1 2024 May 13, 2024	BUY	$27.7 - $35.48 $4.58 Million - $5.87 Million	165,500 Added 9.64%	1,882,197 $55 Million
Q4 2023 Feb 13, 2024	BUY	$26.32 - $34.31 $2.7 Million - $3.52 Million	102,700 Added 6.36%	1,716,697 $57.9 Million
Q3 2023 Nov 14, 2023	BUY	$30.68 - $40.09 $1.21 Million - $1.58 Million	39,300 Added 2.5%	1,613,997 $49.5 Million
Q2 2023 Aug 11, 2023	BUY	$36.12 - $47.5 $570,696 - $750,500	15,800 Added 1.01%	1,574,697 $63.1 Million
Q1 2023 May 12, 2023	SELL	$35.53 - $43.38 $1 Million - $1.22 Million	-28,200 Reduced 1.78%	1,558,897 $63.6 Million
Q4 2022 Feb 13, 2023	SELL	$38.19 - $57.45 $6.35 Million - $9.56 Million	-166,400 Reduced 9.49%	1,587,097 $61.3 Million
Q3 2022 Nov 14, 2022	SELL	$51.24 - $58.89 $10.9 Million - $12.5 Million	-212,000 Reduced 10.79%	1,753,497 $93.3 Million
Q2 2022 Aug 12, 2022	BUY	$51.49 - $81.64 $5.38 Million - $8.53 Million	104,500 Added 5.62%	1,965,497 $115 Million
Q1 2022 May 13, 2022	BUY	$60.03 - $76.49 $708,354 - $902,581	11,800 Added 0.64%	1,860,997 $142 Million
Q4 2021 Feb 11, 2022	SELL	$47.97 - $62.21 $5.74 Million - $7.44 Million	-119,600 Reduced 6.07%	1,849,197 $111 Million
Q3 2021 Nov 12, 2021	SELL	$54.64 - $61.3 $5 Million - $5.61 Million	-91,530 Reduced 4.44%	1,968,797 $110 Million
Q2 2021 Aug 13, 2021	SELL	$59.18 - $69.99 $15.1 Million - $17.8 Million	-254,470 Reduced 10.99%	2,060,327 $125 Million
Q1 2021 May 13, 2021	SELL	$59.31 - $78.82 $18.4 Million - $24.5 Million	-310,262 Reduced 11.82%	2,314,797 $162 Million
Q4 2020 Feb 10, 2021	SELL	$50.47 - $66.26 $7.82 Million - $10.3 Million	-155,038 Reduced 5.58%	2,625,059 $157 Million
Q3 2020 Nov 13, 2020	SELL	$51.97 - $63.0 $3.67 Million - $4.45 Million	-70,700 Reduced 2.48%	2,780,097 $167 Million
Q2 2020 Aug 13, 2020	BUY	$30.8 - $52.47 $11.8 Million - $20.1 Million	382,655 Added 15.5%	2,850,797 $150 Million
Q1 2020 May 14, 2020	BUY	$28.4 - $50.7 $19.1 Million - $34 Million	670,804 Added 37.32%	2,468,142 $82.8 Million
Q4 2019 Feb 13, 2020	BUY	$36.31 - $46.83 $21.1 Million - $27.3 Million	582,238 Added 47.92%	1,797,338 $81.4 Million
Q3 2019 Nov 13, 2019	BUY	$35.66 - $44.99 $4.38 Million - $5.53 Million	122,900 Added 11.25%	1,215,100 $46.3 Million
Q2 2019 Aug 12, 2019	BUY	$36.57 - $47.97 $1.05 Million - $1.37 Million	28,600 Added 2.69%	1,092,200 $47.5 Million
Q1 2019 May 14, 2019	BUY	$36.47 - $42.17 $25.8 Million - $29.9 Million	708,300 Added 199.35%	1,063,600 $40.5 Million
Q4 2018 Feb 13, 2019	BUY	$41.31 - $52.16 $14.7 Million - $18.5 Million	355,300 New	355,300 $15.3 Million

Others Institutions Holding PCRX

# of Institutions

260

Shares Held

49.8M

Call Options Held

1.03M

Put Options Held

139K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.18B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account